Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak and Najjari Discussed the Cooperation between Lebanon and Egypt in the Exchange of Medicines

 
Minister of Public Health Jamil Jabak received UN Special coordinator for Lebanon Philippe Lazzarini. Both discussed the collaboration between the Ministry of Public Health and all the UN organizations working in Lebanon, such as UNIFIL, UNRWA or UNESCO. Lazzarini reiterated the continuing support to the activities of the Ministry of Public Health and follow-up of the donor countries’ programs that are related to the health care sector, in addition to building a joint collaboration in development projects between Lebanon and the United Nations and working on the establishment of better relationships.
 
The Egypt ambassador Nazih Najjari visited also Minister Jabak and stressed the importance of the economic collaboration between the two countries, in particular in the field of medicines. Najjari hoped that Jabak would review the hospitalization systems related to the Egyptian community in Lebanon and whether it is possible to develop the systems while paying attention to the health conditions of the community.
 
Jabak also met with UNRWA Director General in Lebanon Claudio Cordone who presided over a delegation from the agency. “The meeting discussed the collaboration between both parties to ensure the access of Palestinians in Lebanon to health, medical and hospitalization services they need,” Cordone stated.
 
Jabak received a delegation from the board of pharmacists in Lebanon headed by Ghassan Al Amin. Both discussed the situation of health care sector in Lebanon, in particular the medicines dossier and the ways to reduce their costs. It was agreed to form a joint committee to discuss the means to achieve this goal.
 
Jabak then met with the ambassador of the Association of the Malta knights Henry D’Aragon accompanied by the chargé d’affaires François Abi Saab and the representative of the association at the Ministry Khaled Kaskas. D’Aragon stressed the Association’s commitment to preserve the best relationships with Lebanon, indicating readiness to develop and improve them.
    1
    ...
ATC Name B/G ↓ Ingredients Dosage Form Price
M03BX01 BACLOCALM G Baclofen - 25mg 25mg Tablet 928,595 L.L
M03BX01 BACLOCALM G Baclofen - 10mg 10mg Tablet 589,947 L.L
S01EA05 BGLAU G Brimonidine tartrate - 0.2% 0.2% Drops solution 638,325 L.L
S01EA05 BRIMO G Brimonidine tartrate - 0.2% 0.2% Drops solution 658,483 L.L
C01EB17 BRADIREM G Ivabradine (HCl) - 5mg 5mg Tablet, film coated 1,134,203 L.L
S01EA05 BRIMOGAN G Brimonidine tartrate - 0.2% w/v 0.2% w/v Drops solution 483,783 L.L
C01EB17 BRAVIGO G Ivabradine (HCl) - 5mg 5mg Tablet, film coated 1,237,679 L.L
S01EA05 BRIMONIDINE BIOGARAN G Brimonidine tartrate - 2mg/ml 0.2% Drops solution 412,560 L.L
C01EB17 BRADIREM G Ivabradine (HCl) - 7.5mg 7.5mg Tablet, film coated 1,134,203 L.L
C01EB17 BRAVIGO G Ivabradine (HCl) - 7.5mg 7.5mg Tablet, film coated 1,237,679 L.L
D07AC01 BETASONE G Betamethasone (valerate) - 1mg/g 1mg/g Cream 120,306 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORTEZOMIB ACCORD G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 14,169,600 L.L
L01XG01 BORTEZOMIB PHARMINICIO G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB SHILPA G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 9,902,420 L.L
L01XG01 BORTEZOMIB SPC G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 15,743,401 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 51,483,159 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated 51,483,159 L.L
L03AX03 BCG-MEDAC G BCG seed RIVM derived from seed 1173-P2 - 2x10? to 3x10? viable units Injectable powder for suspension+diluent L.L
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,817,857 L.L
C03CA01 BIOLASOMIDE G Furosemide - 40mg 40mg Tablet 181,419 L.L
N07BC01 BUPENSAN G Buprenorphine - 8mg 8mg Tablet 1,259,180 L.L
M05BA06 BONAFOR G Ibandronic acid (monosodium monohydrate) - 150mg 150mg Tablet, film coated 383,955 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 8mg 8mg Tablet 1,115,389 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 2mg 2mg Tablet 563,070 L.L
L01AA09 BENDAVIVAL G Bendamustine HCl - 100mg 100mg Injectable concentrated powder for solution L.L
D07CC01 BETAFUCIN G Fusidic acid - 20mg/g, Betamethasone valerate - 1mg/1g Cream 210,983 L.L
D07CC01 BETASONE-N G Neomycin (sulfate) - 3.5mg/g, Betamethasone (valerate) - 1mg/g Cream 398,033 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026